{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-049669","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.279881+00:00","generated_at":"2026-05-29T09:41:18.815412+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies","bullets":["Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).","Visual acuity improvement in treated eyes across multiple cohorts (006-001, 007-001, 006-004) compared to untreated.","Treated mutant group shows better outcomes than untreated mutant in LL VA change over 6 months.","Presentation posted on company website December 3, 2024 and may be used in investor discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-049669","json":"https://secwatch.observer/filing/0001628280-24-049669.json","markdown":"https://secwatch.observer/filing/0001628280-24-049669.md","text":"https://secwatch.observer/filing/0001628280-24-049669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/0001628280-24-049669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/ocgn-20241203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:41:18.815412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}